Histologic, morphometric, and biochemical evolution of vein bypass grafts in a nonhuman primate model. III. Long-term changes and their modification by platelet inhibition with aspirin and dipyridamole.
The objectives of this study were to elucidate the long-term influence on vein bypass grafts of platelet inhibition and its late discontinuation. Cephalic vein grafts were interposed bilaterally in the femoral arteries of stump-tailed macaque monkeys fed a diet that sustains plasma cholesterol levels of approximately 225 mg/dl. Fifteen animals were divided into three groups of five animals each. Group I received no medications and served as a control group. Group II received for the full duration of the study a combination of aspirin, 80 mg/day, and dipyridamole, 50 mg/day. Group III received the same regimen of platelet inhibition as in group II during the first 9 months, but were not treated during the subsequent 9-month interval. Grafts were excised for analysis from groups I and II at both 9 and 18 months and from group III at 18 months. Cholesterol content in group I grafts was 470 +/- 89 micrograms/100 mg at 9 months and 388 +/- 127 micrograms/100 mg at 18 months. In group II grafts, cholesterol content was 208 +/- 72 micrograms/100 mg at 9 months (p less than 0.001 compared with group I) and 266 +/- 84 micrograms/100 mg at 18 months. In group III grafts, cholesterol content was 249 +/- 71 micrograms/100 mg at 18 months. Differences in cholesterol content among the three groups of grafts at 18 months were not found to be statistically significant. Stepwise regression analysis at 18 months showed that cholesterol content was best predicted by medial fibrosis (r2 = 0.66) followed by abundance of foam cells (increase in r2 = 0.26) in group I, by fibrin in group II (r2 = 0.63), and by prevalence of macrophages in group III (r2 = 0.74). In all groups, platelets, fibrin, and polymorphonuclear leukocytes were less abundant than they had been at 3 months. Cross-sectional area occupied by the intima was not influenced by platelet inhibition.
Boerboom
L E
LE
Department of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee.
Olinger
G N
GN
Liu
T Z
TZ
Rodriguez
E R
ER
Ferrans
V J
VJ
Kissebah
A H
AH
D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D002784:Cholesterol / Q000032:analysis; D004176:Dipyridamole / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004730:Endothelium, Vascular / Q000473:pathology; D005263:Femoral Artery / Q000601:surgery*; D005355:Fibrosis; D005487:Foam Cells / Q000473:pathology; D005542:Forearm / Q000098:blood supply; D008251:Macaca; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors; D013997:Time Factors; D014680:Veins / Q000032:analysis / Q000187:drug effects / Q000473:pathology / Q000637:transplantation*
D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D002784:Cholesterol; D001241:Aspirin